This document is an internal Drug Enforcement Administration quality system document. The document is updated periodically and is current as of August 2, 2023 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some document in their...

This document is an internal Drug Enforcement Administration quality system document. The document is updated periodically and is current as of August 2, 2023 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some document in their...

This document is an internal Drug Enforcement Administration quality system document. The document is updated periodically and is current as of August 2, 2023 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some document in their...

This document is an internal Drug Enforcement Administration quality system document. The document is updated periodically and is current as of August 2, 2023 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some document in their...

This document is an internal Drug Enforcement Administration quality system document. The document is updated periodically and is current as of August 2, 2023 and is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some document in their...

On August 1, 2023, the Drug Enforcement Administration (DEA) and U.S. Food and Drug Administration (FDA) issued a joint letter updating the public on the ongoing prescription stimulant shortages impacting patients across the United States and actions to resolve these shortages. The DEA and FDA are committed to working together...

Chair Biggs, Ranking Member Jackson Lee, and distinguished members of the subcommittee: On behalf of the Department of Justice (Department), and in particular the nearly 10,000 employees working at the Drug Enforcement Administration (DEA), thank you for the opportunity to appear before you today to discuss DEA’s work to save...

Americans today are experiencing the most devastating drug crisis in our nation’s history. This is because one drug—fentanyl—has transformed the criminal landscape. Fentanyl is exceptionally cheap to make, exceptionally easy to disguise, and exceptionally deadly to those who take it. It is the leading cause of death for Americans between...

“Today’s announcement is a considerable step forward in our unrelenting fight against fentanyl, targeting the threat where it starts. These companies and individuals are alleged to have knowingly supplied drug traffickers, in the United States and Mexico, with the ingredients and scientific know-how needed to make fentanyl – a drug...

Americans today are experiencing the most devastating drug crisis in our nation’s history. This is because one drug—illicit fentanyl—has transformed the criminal landscape. Illicit fentanyl is exceptionally cheap to make, exceptionally easy to disguise, and exceptionally deadly to those who take it. It is the leading cause of death for...